Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385549 | 1.00 | ALOX5AP (0.43) | ALOX5APNOTUMBCHEKDM1ANAMPT | |
| SCHEMBL5332810 | 0.88 | AKT1 (0.45) | ALOX5APNOTUMBCHEKDM1ANAMPT | |
| SCHEMBL30681234 | 0.88 | AKT1 (0.45) | ALOX5APNOTUMBCHEKDM1ANAMPT | |
| SCHEMBL5332801 | 0.88 | AKT1 (0.45) | ALOX5APNOTUMBCHEKDM1ANAMPT | |
| SCHEMBL30681300 | 0.88 | AKT1 (0.45) | ALOX5APNOTUMBCHEKDM1ANAMPT | |
| SCHEMBL19056685 | 0.87 | NOTUM (0.44) | NOTUMBCHEKDM1ANAMPT | |
| SCHEMBL31158605 | 0.87 | NOTUM (0.44) | NOTUMBCHEKDM1ANAMPT | |
| SCHEMBL30681293 | 0.86 | ALOX5AP (0.42) | ALOX5APNOTUMBCHENAMPTALDH1A1 | |
| SCHEMBL6394797 | 0.85 | ALOX5AP (0.41) | ALOX5APNOTUMBCHEKDM1ANAMPT | |
| SCHEMBL1760601 | 0.85 | DRD2 (0.47) | ALOX5APNOTUMBCHEKDM1ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | ALOX5AP 702/4885NOTUM 1979/4885BCHE 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.